Roche Holding AG (XSWX:ROG) 3-Year FCF Growth Rate

: 1.20% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Roche Holding AG's Free Cash Flow per Share for the six months ended in Dec. 2023 was CHF6.87.

During the past 12 months, Roche Holding AG's average Free Cash Flow per Share Growth Rate was -13.20% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 1.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -3.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Roche Holding AG was 46.20% per year. The lowest was -20.20% per year. And the median was 6.50% per year.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG 3-Year FCF Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's 3-Year FCF Growth Rate falls into.

Roche Holding AG 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Roche Holding AG (XSWX:ROG) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Roche Holding AG 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG (XSWX:ROG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:ROG) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBY:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.